Dynamics of cytokine profile parameters during olokizumab therapy: Results of a single-center randomized controlled trial
Open Access
- 31 October 2026
- journal article
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (5) , 513-522
Abstract
The aim – to evaluate the effect of olokizumab (OKZ) on the levels of proand anti-inflammatory cytokines, chemokines, and growth factors in patients with rheumatoid arthritis (RA) and comorbid depression. Material and methods . A total of 125 patients with RA and comorbid depression were included; 102 (81.6%) women, with a mean age of 48.5±12.6 years. The majority (86.4%) had high RA activity and had failed stable 12-week therapy with synthetic disease-modifying antirheumatic drugs (DMARDs). Thirty-four (27.2%) patients had failed one or more biological agents (BAs). At week 0, all patients were randomized using the sequential numbers method in a 2:2:1 ratio into one of three groups: Group 1 received treatment with sDMARDs+OKZ 64 mg subcutaneously once every 4 weeks (4N) (n=49); Group 2 – sDMARDs+OKZ 64 mg subcutaneously 4N + psychopharmacotherapy (PPT) (n=51); Group 3 – sDMARDs+PPT (n=25). The study duration was 24 weeks. The concentration of 27 cytokines in the serum was measured using multiplex xMAP technology on a Bio-Plex array system analyzer (Bio-Rad, USA). Results . After 12 weeks of OKZ therapy, a significant decrease in the level of proinflammatory cytokines – interleukin (IL) 2; anti-inflammatory cytokines – IL-4, IL-10, IL-13, IL-1 receptor antagonist (IL-1Ra); chemokines – macrophage inflammatory protein 1α (MIP-1α), interferon γ-stimulated protein 10 (IP-10), IL-8; growth factors – IL-7, fibroblast growth factor (FGF), platelet-derived growth factor (PDGF-bb); an increase in the level of anti-inflammatory cytokines – IL-5, IL-9, Eotaxin and tumor necrosis factor α (TNF-α); after 24 weeks of therapy – a decrease in the level of pro-inflammatory cytokines – IL-2, IL-15; anti-inflammatory cytokines – IL-4, IL-13, IL-1Ra; chemokines – monocyte chemotactic protein-1 (MCP-1), MIP-1α, IL-8; growth factors – IL-7, PDGF-bb; increased levels of Eotaxin and TNF-α. Conclusion. The use of OKZ is accompanied by a decrease in the level of proinflammatory cytokines, chemokines, and growth factors, and an increase in the content of TNF-α.Keywords
This publication has 62 references indexed in Scilit:
- Characterization and Function of Tumor Necrosis Factor and Interleukin‐6–Induced Osteoclasts in Rheumatoid ArthritisArthritis & Rheumatology, 2021
- Association of High Serum Interleukin‐6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc AnalysisArthritis & Rheumatology, 2020
- Evaluation of Serum Interleukin‐6 Level as a Surrogate Marker of Synovial Inflammation and as a Factor of Structural Progression in Early Rheumatoid Arthritis: Results From a French National Multicenter CohortArthritis Care & Research, 2014
- Biomarkers of Rheumatoid Arthritis–Associated Interstitial Lung DiseaseArthritis & Rheumatology, 2014
- Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progressionClinical Rheumatology, 2013
- Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score With 28‐Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score‐II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index‐5 (RADAI‐5), Chronic Arthritis Systemic Index (CASI), Patient‐Based Disease Activity Score With ESR (PDAS1) and Patient‐Based Disease Activity Score Without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI‐RA)Arthritis Care & Research, 2011
- Acquisition of regulatory function by human CD8+ T cells treated with anti‐CD3 antibody requires TNFEuropean Journal of Immunology, 2010
- Historical insights into cytokinesEuropean Journal of Immunology, 2007
- Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factorEuropean Journal of Immunology, 2000
- Tumor necrosis factor (TNF) receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1European Journal of Immunology, 1998